BeOne Medicines (NASDAQ:ONC) Downgraded by Jefferies Financial Group to Hold

Jefferies Financial Group cut shares of BeOne Medicines (NASDAQ:ONC) from a buy rating to a hold rating in a research note released on Monday, Marketbeat.com reports. The firm currently has $290.00 price objective on the stock, down from their previous price objective of $420.00.

Several other research analysts have also recently weighed in on ONC. Wall Street Zen cut shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Royal Bank Of Canada lifted their target price on BeOne Medicines from $417.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Truist Financial boosted their target price on BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Barclays upped their price target on BeOne Medicines from $394.00 to $405.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $389.18.

BeOne Medicines Stock Up 2.0%

Shares of NASDAQ:ONC opened at $289.65 on Monday. The company has a quick ratio of 3.08, a current ratio of 3.41 and a debt-to-equity ratio of 0.22. The firm has a market cap of $31.76 billion, a P/E ratio of 114.94 and a beta of 0.53. BeOne Medicines has a 12 month low of $196.45 and a 12 month high of $385.22. The company’s 50-day moving average price is $333.91 and its two-hundred day moving average price is $329.84.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%.The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. As a group, research analysts forecast that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of BeOne Medicines stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 2,665 shares of company stock valued at $902,792 over the last quarter. 6.62% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. EFG International AG bought a new stake in BeOne Medicines in the fourth quarter valued at about $25,000. Anchor Investment Management LLC bought a new position in BeOne Medicines during the second quarter worth about $26,000. Leonteq Securities AG bought a new position in BeOne Medicines during the fourth quarter worth about $35,000. Daiwa Securities Group Inc. acquired a new position in shares of BeOne Medicines during the 2nd quarter worth about $35,000. Finally, CWM LLC grew its position in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. 48.55% of the stock is currently owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.